WCK-4234 free base
WCK-4234 free base is a diazabicyclooctane β-lactamase inhibitor and susceptibility restorer. WCK-4234 free base lacks direct antibacterial activity. WCK-4234 free base inhibits class A, C, D β-lactamases and extended-spectrum β-lactamases to potentiate Imipenem (HY-B1369A) and Meropenem (HY-13678) activity against Gram-negative pathogens. WCK-4234 free base can be used for the research of gram-negative bacterial infections and β-lactamase-mediated carbapenem-resistant bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 1706523-58-1
- Formula: C7H9N3O5S
- Molecular Weight:247.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Beta-lactamase Isoforms
More
Biological Activity
Description
In Vitro
WCK-4234 (4-8 mg/L) free base potently potentiates imipenem and meropenem against clinical Enterobacteriaceae isolates with KPC, OXA-48, or OXA-181 carbapenemases, or combinations of AmpC/ESBL activity and impermeability, reducing geometric mean carbapenem MICs to ≤1 mg/L, but does not potentiate carbapenems against MBL-producing Enterobacteriaceae[2].
WCK-4234 (4-8 mg/L) free base potentiates imipenem and meropenem against AmpC-hyperproducing, OprD-deficient, and OXA-181-producing Pseudomonas aeruginosa isolates, reducing carbapenem MIC50s by 4-fold or more, but does not potentiate carbapenems against MBL-producing Pseudomonas aeruginosa[2].
WCK-4234 (4-8 mg/L) free base potently potentiates imipenem and meropenem against OXA-23-producing and hyperproduced OXA-51-producing Acinetobacter baumannii isolates, reducing geometric mean carbapenem MIC50s by 8-40-fold to ≤2 mg/L in most cases, but does not potentiate carbapenems against MBL-producing Acinetobacter baumannii[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1706523-58-1
-
Molecular Weight 247.23
-
Formula C7H9N3O5S
-
SMILES
O=S(ON1[C@@]2([H])C[N@]([C@@H](CC2)C#N)C1=O)(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
[1]. Iregui A, et al. Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City. Antimicrob Agents Chemother. 2019;64(1):e01666-19. Published 2019 Dec 20. [Content Brief]
[2]. Mushtaq S, et al. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1688-1695. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- WCK-4234
- 1706523-58-1
- WCK4234
- WCK 4234
- Beta-lactamase
- Bacterial
- Pseudomonas aeruginosa
- extended-spectrum β-lactamases
- Gram-negative pathogens
- carbapenem-resistant bacterial infections
- Enterobacteriaceae
- β-lactamase inhibitor
- Acinetobacter baumannii
- class A β-lactamases
- class D β-lactamases
- class C β-lactamases
- Inhibitor
- inhibitor
- inhibit